UK: Brexit And The Impact On Clinical Research

On General Election day 2017, Jackie Mulryne, Ewan Townsend, & Lincoln Tsang, Arnold & Porter Kaye Scholer LLP, discuss the impact Brexit will have on clinical research

The U.K. Government triggered the formal procedure to exit the European Union on March 29, 2017. The U.K. and the EU institutions are now determining the arrangements for the orderly withdrawal of the U.K. Unless an extension is agreed, this process must be completed by March 29, 2019, and so while negotiations on the terms of the U.K.'s departure have not yet officially begun, EU institutions and government departments in the U.K. have started their planning activities.

Unsurprisingly, the nature of the U.K.'s departure and its relationship with the EU once it ceases to be a Member State has attracted a great deal of speculation. There is considerable uncertainty surrounding how Brexit will actually work, not least because no Member State has left the EU in its current form.

Once the U.K. leaves the EU, it will have no legal obligation to abide by the EU Treaty principle of "sincere cooperation" with EU institutions, and will not be required to comply with EU laws relevant to clinical research. This will clearly affect the regulation of multi-center clinical trials that involve the U.K. If the parties wish to maintain the current cooperative framework, it will have to be rebuilt through agreement.

What are the options?

There has been a great deal of speculation about whether the future relationship between the U.K. and the EU will adopt one of the existing trading models operated by countries such as Norway and Canada. However, none of these models take full account of the unique situation of the U.K., which has been a key Member State for nearly 45 years, and where EU laws have been fully integrated into the fabric of the U.K. legal system.

At present, it is widely reported that the U.K. government intends to pursue a "clean break" from the EU. However, the Great Repeal Bill (the key legislation that will be used to implement Brexit in the U.K.) contemplates converting all directly applicable EU laws into U.K. law, and these laws will continue to apply until U.K. legislators decide otherwise. The Bill will also preserve those laws the U.K. has made in order to implement its EU obligations. It follows that the Great Repeal Bill will, at least in the short term, preserve the legislative framework for clinical trials in the U.K. That said, the Great Repeal Bill will also grant the Government significant powers to make adjustments and corrections in relation to those directly applicable EU laws that do not operate appropriately after withdrawal. It is uncertain as to how and whether U.K. Ministers will exercise such power and in what circumstances.

What impact will Brexit have on clinical research in the UK?

The EU laws that govern pharmaceuticals and medical technologies are all based on the EU's internal market principles. In the context of clinical trials for pharmaceuticals, the initial directive, Directive 2001/20/EC, was adopted in 2001 to facilitate clinical trials conducted in the region. The process has evolved since the Directive's introduction, and close cooperation amongst national regulatory authorities has facilitated and streamlined the approval of multi-center trials across the EU. This cooperative process was reflected and formalized by the recently adopted Regulation 536/2014/EU, which is expected to come into operation in 2018.

Until it formally exits the EU, the U.K. will continue to be subject to this legislation, and also to enjoy the broader benefits afforded to all EU Member States, including (a) taking an active role in developing regulatory policy, (b) participating in the EU process for approving clinical trials that will be conducted in more than one Member State, and (c) accessing the EU portal for clinical trials, once it has been finalized. Whether the U.K. will be able to enjoy the same level of benefits as a "third country" outside the EU will depend on the agreement reached between the U.K. Government and the EU institutions during the forthcoming negotiations.

We set out below certain key considerations that will need to be addressed in order to maintain a fertile environment for collaborative clinical research in the U.K. post-Brexit:

1) Investment in clinical research

Over the last few decades, the U.K. has continued to punch above its weight in terms of innovative scientific research. Clinical or translational research is increasingly collaborative between industry, academia and governmental organizations. The U.K. has been the second largest recipient of EU funding for clinical research after Germany, and unsurprisingly the institutions which benefit from this funding have raised concerns about whether they will continue to access it after Brexit. While the U.K. Government has indicated an ongoing commitment to scientific research, it is uncertain whether such a commitment will be realized, particularly in view of increasing pressures on public expenditure.

2) People

Researchers are the engine that drives the progress of research, and a country's research base is critically dependent on the individual contributions of the researchers affiliated with its institutions. A trial site is selected by its expertise, know-how and personnel. Concerns have been raised by various royal societies and academies of sciences that once EU rules around free movement of workers cease to apply, the U.K. may no longer be able to attract and retain the talent required to undertake multidisciplinary and complex clinical and translational research.

3) Management of clinical trials

A country's attractiveness for clinical research is linked to commercial considerations around launch strategy and reimbursement, and the U.K. may become less attractive as a country in which to launch new products if it is not part of the EU regulatory network. Further, any divergence of U.K. and EU rules after Brexit will increase the complexities, administrative burden and cost for companies in conducting clinical research in the U.K. It remains unclear whether, post-Brexit, EU institutions will grant the U.K. regulator access to the EU databases that are being set up under the Regulation, which will be critical to proper management of multi-center trials, or if additional fees will be imposed in order to do so. Nor is it clear whether the U.K. will be able to participate in the 'streamlined' clinical trial approval process introduced by the new Regulation.

4) Supplies of investigational medicinal products

Once EU rules around free movement of products cease to apply, there will be a hard border between the U.K. and the EU. This is likely to have a significant impact on the export of investigational medicinal products manufactured in the U.K. for use in trial sites located in the EU, and vice versa. Whatever is finally agreed, there are likely to be cost implications associated with duplication of the administrative and regulatory procedures required in order to enable clinical studies to be conducted on a cross-border basis.

All these factors (if not fully recognized and addressed) will render the U.K. less attractive for clinical research. The uncertainty has worried some in the sector, who are concerned about the U.K.'s competitiveness in an increasingly globalised and regionally competitive research environment.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
In association with
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.

Disclaimer

Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.

Registration

Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.

Cookies

A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.

Links

This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.

Mail-A-Friend

If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.

Security

This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.